Why the study?
Inflammation is a key driver of residual CV risk in CKD, but the extent of its association with obesity in this population is underexplored.
Does finerenone reduce composite CV events irrespective of baseline hsCRP and BMI in adults with CKD and T2D?
Population
12,864 adults with CKD and T2D
Comparison
hsCRP levels overall and by BMI categories
Design
Participant-level pooled analysis
Key result
Higher baseline hsCRP levels were associated with a higher rate of composite CV events (aHR per hsCRP doubling 1.11; 95% CI 1.07-1.14), primarily among persons with elevated BMI.
Authors
Loading...
Highlights BMI-dependent inflammatory CV risk in CKD/T2D; confirms residual pathway but leaves targeted anti-inflammatory strategies open.
Observational (n=12,864)
Does finerenone reduce composite CV events irrespective of baseline hsCRP and BMI in adults with CKD and T2D?
Hazard Ratio: 1.11 (95% CI 1.07–1.14)
In patients with CKD and T2D, low-grade inflammation is associated with increased CV risk, particularly in those with overweight/obesity, but the CV benefits of finerenone remain consistent regardless of baseline hsCRP or BMI.
Ostrominski et al. (2026) conducted an observational in Chronic Kidney Disease and Type 2 Diabetes (n=12,864). Higher baseline hsCRP levels vs. Lower baseline hsCRP levels was evaluated on composite CV events (aHR 1.11, 95% CI 1.07-1.14). Higher baseline hsCRP levels were associated with a higher rate of composite CV events (aHR per hsCRP doubling 1.11; 95% CI 1.07-1.14), primarily among persons with elevated BMI.